Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017

FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years

MRI contrast agent can now be used to detect disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in youngest patients, including term neonates

FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years

September 6, 2017 — Guerbet LLC USA announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine) for intravenous use with magnetic resonance imaging (MRI) in pediatric patients under two years old, including term neonates. The contrast agent can be used to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS).

Dotarem was previously approved for this use in patient populations over the age of two.

This supplemental indication fulfills a post marketing requirement, acknowledged when Dotarem was first registered in March 2013, to strictly comply with the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c).

The FDA's review was based on a study showing that at the standard dose (0.1 mmol/kg),1 the pharmacokinetic (PK) and safety profiles in pediatric patients under two were similar to those of older children and adults.

The clinical study enrolled 51 pediatric patients in nine centers, with ages spanning from term neonates to 23 months and with normal renal function. It evaluated 45 pediatric patients for PK profile and safety, including five subjects aged less than one month and nine subjects aged one to three months. It assessed efficacy in a subset of 28 subjects who underwent an MRI examination of brain, spine and associated tissues.

In this pediatric population the observed safety profile of Dotarem was consistent with what has been reported in older populations. In one patient, rash was reported as a moderate adverse event (AE). Serious AEs unrelated to Dotarem were reported in one out of 45 patients. Evaluation of images from contrast-enhanced MRI of the CNS supported extrapolation of CNS efficacy findings reported in adults and older children.

Dotarem is the only macrocyclic and ionic gadolinium-based contrast medium (a kind that provides high molecular stability) available in the United States.

For more information: www.guerbet.com

Read the related article "Recent Trends and Developments in Contrast Media."
 

 

References

1. Dotarem (gadoterate meglumine) US Prescribing Information

Related Content

Toshiba Vantage Galan 3T XGO Edition MRI Features New Advanced Gradient

MRI of the brain performed on the Galan 3T utilizing the 32-channel Head SPEEDER Coil

Technology | Magnetic Resonance Imaging (MRI) | December 11, 2017
Toshiba Medical, a Canon Group company, demonstrated the Vantage Galan 3T XGO Edition with the all-new Saturn X...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Philips Debuts IQon Elite Spectral CT Scanner at RSNA 2017
Technology | Computed Tomography (CT) | December 11, 2017
At the 2017 Radiological Society of North America (RSNA) Annual Meeting, Philips unveiled the IQon Elite Spectral CT,...
Siemens Healthineers Introduces Mammomat Revelation Mammography System for Improved Biopsy Workflow
Technology | Mammography | December 11, 2017
Siemens Healthineers unveiled the new Mammomat Revelation premium mammography platform at the 2017 Radiological Society...
Breast Cancer Screening Performance Impacted by Mean Mammographic Compression Pressure
News | Mammography | December 08, 2017
Dutch researchers demonstrated a strong relationship between compression pressure in mammography and breast cancer...
Sponsored Content | Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Technology | Neuro Imaging | December 07, 2017
Deep learning artificial intelligence (AI) medical company DeepRadiology  announced the world's first computed...
Sponsored Content | Videos | Advanced Visualization | December 07, 2017
Dianna Bardo M.D., director of body MR and co-director of the 3-D Innovation Lab at Phoenix Children's Hospital.
Sponsored Content | Videos | Artificial Intelligence | December 07, 2017
Adam Flanders, M.D., co-director, neuroradiology and vice-chair of informatics at Jefferson University Hospitals, Phi
Toshiba Highlights Ultra-High Resolution CT at RSNA 2017
News | Computed Tomography (CT) | December 06, 2017
December 6, 2017 — Toshiba Medical, a Canon Group company, showcased the Aquilion Precision, what it calls the world’
Overlay Init